Atopic dermatitis (AD) and psoriasis are T cell-mediated inflammatory diseases : a Th2-component with interleukin (IL)-4 and IL-13 production in AD, a Th17/IL-23 and TNF response in psoriasis. Although the coexistence of both diseases is rare, they can be seen as parts of a same spectrum (1). Dupilumab, an anti-IL-4/IL-13 monoclonal antibody, has recently been approved for the treatment of moderate to severe AD. Beyond its efficacy, it may induce cutaneous adverse reactions.
No takes yet. Share an insight, caveat, or question.
Jaulent et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: